Ken Griffin Mirum Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$23.57 - $34.85 $115,493 - $170,765	-4,900 Reduced 33.33%	9,800 $335,000
Q1 2024 May 15, 2024	SELL	$24.92 - $30.02 $179,424 - $216,144	-7,200 Reduced 32.88%	14,700 $369,000
Q4 2023 Feb 14, 2024	BUY	$27.14 - $34.93 $341,964 - $440,118	12,600 Added 135.48%	21,900 $646,000
Q3 2023 Nov 14, 2023	SELL	$24.63 - $32.85 $39,408 - $52,560	-1,600 Reduced 14.68%	9,300 $293,000
Q2 2023 Aug 14, 2023	BUY	$23.51 - $30.09 $173,974 - $222,666	7,400 Added 211.43%	10,900 $281,000
Q1 2023 May 15, 2023	SELL	$19.19 - $24.1 $67,165 - $84,350	-3,500 Reduced 50.0%	3,500 $84,000
Q4 2022 Feb 14, 2023	BUY	$17.59 - $23.83 $123,130 - $166,810	7,000 New	7,000 $136,000

172

54.2M

96.1K

54.8K

Ticker MIRM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,751,700
Market Cap $1.43B
Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.